Akebia Therapeutics Inc. AKBA

NAS: AKBA | ISIN: US00972D1054   17/11/2025
1,760 USD (+5,39%)
(+5,39%)   17/11/2025

5 september 2024 · Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo® (vadadustat) for Patients on Dialysis · Persbericht

3 september 2024 · Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

26 augustus 2024 · Akebia Therapeutics to Present at Upcoming Investor Conferences · Persbericht

8 augustus 2024 · Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights · Persbericht

2 augustus 2024 · Akebia Therapeutics to Report Second Quarter 2024 Financial Results and Discuss Recent Business Highlights · Persbericht

1 augustus 2024 · Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

29 juli 2024 · Akebia Therapeutics to Present at Upcoming Investor Conferences · Persbericht

11 juli 2024 · Akebia Therapeutics Provides Update on Continued Momentum of Commercial Launch of Vafseo® (vadadustat) Tablets · Persbericht

1 juli 2024 · Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

27 juni 2024 · Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference · Persbericht

24 juni 2024 · Akebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer · Persbericht

3 juni 2024 · Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

23 mei 2024 · Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference · Persbericht

14 mei 2024 · Akebia Therapeutics to Present at the 2nd Annual HCW Bioconnect Investor Conference · Persbericht

9 mei 2024 · Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights · Persbericht

2 mei 2024 · Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights · Persbericht

1 mei 2024 · Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

2 april 2024 · Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

28 maart 2024 · Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis · Persbericht

14 maart 2024 · Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights · Persbericht

Mijn selecties